Bridgebio Oncology Therapeutics, Inc. (BBOT)
2.04
-0.13
(-5.99%)
USD |
NASDAQ |
Nov 06, 16:00
2.08
+0.04
(+1.96%)
After-Hours: 20:00
Bridgebio Oncology Therapeutics Research and Development Expense (Quarterly) : 49.22M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 49.22M |
| March 31, 2026 | 39.80M |
| December 31, 2025 | 38.07M |
| September 30, 2025 | 34.64M |
| Date | Value |
|---|---|
| June 30, 2025 | 27.44M |
| March 31, 2025 | 20.64M |
| December 31, 2024 | 19.54M |
| September 30, 2024 | 17.73M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | 42.14M |
| IRulya Therapeutics, Inc. | 5.461M |
| PepGen Inc. | 12.22M |
| Q32 Bio, Inc. | 5.149M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |